---
title: Cerebral Energy State in Cardiac Surgery
nct_id: NCT02846818
overall_status: COMPLETED
phase: NA
sponsor: Odense University Hospital
study_type: INTERVENTIONAL
primary_condition: Postoperative; Dysfunction Following Cardiac Surgery
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02846818.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02846818"
ct_last_update_post_date: 2016-07-27
last_seen_at: "2026-05-12T06:53:15.513Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Cerebral Energy State in Cardiac Surgery

**Official Title:** Continuous Monitoring of Cerebral Energy State During Cardiac Surgery - A Novel Approach Utilizing Intravenous Microdialysis

**NCT ID:** [NCT02846818](https://clinicaltrials.gov/study/NCT02846818)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** Odense University Hospital
- **Conditions:** Postoperative; Dysfunction Following Cardiac Surgery
- **Start Date:** 2015-02
- **Completion Date:** 2015-05
- **CT.gov Last Update:** 2016-07-27

## Brief Summary

Impaired cerebral function remains an important complication of cardiopulmonary bypass (CPB) during cardiac surgery. The aim of the present study is to investigate whether the lactate to pyruvate (LP) ratio obtained by microdialysis (MD) of the cerebral venous outflow reflects a derangement of global cerebral energy state during cardiopulmonary bypass.

## Detailed Description

Patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to usual range MAP (40 to 60 mmHg; n = 5) or intervention group MAP (60 to 80 mmHg; n = 5) during CPB. MD catheters were positioned in a retrograde direction in the internal jugular vein and a reference catheter was inserted into the brachial artery. The relations between LP ratio, MAP, data obtained from bi-frontal NIRS and neurological outcome measures were assessed.

## Eligibility

- **Minimum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion criteria:

* Elective CABG on CPB

Exclusion criteria:

* Acute patients or reoperations
* Patients with epidural catheter
* Previous stroke
* Stenotic carotids
* Ejection fraction (EF) \< 50 %
* Estimated per operative risk \> 5%
```

## Arms

- **Low mean arterial perfusion pressure** (EXPERIMENTAL) — 5 patients undergoing primary, elective coronary artery bypass grafting were randomized to usual range MAP (40 to 60 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
- **High mean arterial perfusion pressure** (EXPERIMENTAL) — 5 patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to intervention group MAP (60 to 80 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.

## Interventions

- **Microdialysis** (PROCEDURE) — Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.

## Primary Outcomes

- **Extracerebral microdialysis parameters** _(time frame: MD parameters were measured intraoperatively and for two hours postoperatively)_ — Does the LP ratio of cerebral venous blood increase significantly during CPB indicating compromised cerebral oxidative metabolism.The analyses included the variables routinely monitored during intracerebral microdialysis: glucose, pyruvate, lactate, glutamate, glycerol and lactate to pyruvate ratio.

## Secondary Outcomes

- **Mini mental state examination (MMSE)** _(time frame: Neurological complications with in 2 days after surgery)_
- **Near-infrared spectroscopy (NIRS)** _(time frame: one day)_

## Locations (1)

- Odense University Hospital, Odense, Fyn, Denmark

## Recent Field Changes (last 30 days)

- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.odense university hospital|odense|fyn|denmark` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02846818.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02846818*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*